262 related articles for article (PubMed ID: 16103880)
1. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
2. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J
Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823
[TBL] [Abstract][Full Text] [Related]
3. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
[TBL] [Abstract][Full Text] [Related]
4. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
5. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.
Fang WB; Ireton RC; Zhuang G; Takahashi T; Reynolds A; Chen J
J Cell Sci; 2008 Feb; 121(Pt 3):358-68. PubMed ID: 18198190
[TBL] [Abstract][Full Text] [Related]
7. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style.
Parri M; Taddei ML; Bianchini F; Calorini L; Chiarugi P
Cancer Res; 2009 Mar; 69(5):2072-81. PubMed ID: 19244130
[TBL] [Abstract][Full Text] [Related]
8. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
11. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J
Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451
[TBL] [Abstract][Full Text] [Related]
12. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
14. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.
Pratt RL; Kinch MS
Mol Cancer Res; 2003 Dec; 1(14):1070-6. PubMed ID: 14707290
[TBL] [Abstract][Full Text] [Related]
15. Differential EphA2 epitope display on normal versus malignant cells.
Coffman KT; Hu M; Carles-Kinch K; Tice D; Donacki N; Munyon K; Kifle G; Woods R; Langermann S; Kiener PA; Kinch MS
Cancer Res; 2003 Nov; 63(22):7907-12. PubMed ID: 14633720
[TBL] [Abstract][Full Text] [Related]
16. A conditional feedback loop regulates Ras activity through EphA2.
Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F
Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464
[TBL] [Abstract][Full Text] [Related]
17. EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
Zelinski DP; Zantek ND; Stewart JC; Irizarry AR; Kinch MS
Cancer Res; 2001 Mar; 61(5):2301-6. PubMed ID: 11280802
[TBL] [Abstract][Full Text] [Related]
18. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS
Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162
[TBL] [Abstract][Full Text] [Related]
19. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.
Larsen AB; Pedersen MW; Stockhausen MT; Grandal MV; van Deurs B; Poulsen HS
Mol Cancer Res; 2007 Mar; 5(3):283-93. PubMed ID: 17374733
[TBL] [Abstract][Full Text] [Related]
20. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.
Taddei ML; Parri M; Angelucci A; Bianchini F; Marconi C; Giannoni E; Raugei G; Bologna M; Calorini L; Chiarugi P
Mol Cancer Res; 2011 Feb; 9(2):149-60. PubMed ID: 21205836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]